Pacira BioSciences, Inc. (PCRX) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025. Pacira BioSciences, Inc. is a biopharmaceutical company focused on non-opioid pain therapies. Its core commercial products include EXPAREL (long-acting local analgesic), ZILRETTA (extended-release intra-articular injection for knee osteoarthritis), and iovera (cryoanalgesia device). In February 2025, the Company completed the acquisition of the remaining 81% of GQ Bio Therapeutics GmbH, securing its proprietary high-capacity adenovirus (HCAd) vector platform and advancing the development of PCRX-201, a gene therapy for knee osteoarthritis.
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | Value (in thousands) |
|---|---|
| Total Revenues | $350,022 |
| Net Product Sales | $347,941 |
| Net (Loss) Income | $(35) |
| Income from Operations | $10,489 |
| Gross Margin | 79% |
| Cash and Cash Equivalents | $300,484 |
| Short-term Investments | $145,380 |
| Total Debt (Carrying Value) | $580,492 |
| Net Cash Provided by Operating Activities | $47,471 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 1% year-over-year (YoY) to $350.0 million. EXPAREL sales grew 4% YoY driven by volume and price increases. ZILRETTA sales declined 3% YoY due to volume decreases during a sales force transition, partially offset by price increases.
- Profitability: The Company reported a near-breakeven net loss of $35,000 for the six months ended June 30, 2025, compared to net income of $27.9 million in the same period in 2024. This decline was primarily due to a $7.0 million legal settlement charge and increased R&D and SG&A expenses.
- Operating Expenses: Total operating expenses increased 12% YoY to $339.5 million.
- R&D: Increased 40% YoY to $53.9 million, driven by clinical trial enrollment for PCRX-201 and ZILRETTA shoulder indications.
- SG&A: Increased 25% YoY to $175.4 million, reflecting expanded sales and marketing efforts and higher stock-based compensation.
- Other Income/Loss: The Company recognized a net loss of $6.3 million in "Other, net" for the six months, primarily due to an $11.0 million impairment of equity investments and convertible notes, partially offset by a $5.9 million realized gain on the GQ Bio investment settlement.
Guidance, Outlook, and Management Commentary
- Strategic Acquisitions: Management highlighted the GQ Bio acquisition as a strategic move to advance the HCAd platform and PCRX-201, eliminating future milestone and royalty obligations associated with the asset.
- Manufacturing Efficiency: In July 2025 (subsequent to the period end), the Company announced the decommissioning of its 45-liter EXPAREL manufacturing suite in San Diego to consolidate production into larger-scale facilities. This is expected to improve gross margins and reduce annual operating expenses by approximately $13.0 million, though it will incur one-time restructuring charges of $2.4–$2.8 million in Q3 2025.
- Legal Settlements: The Company settled patent infringement litigation with eVenus, Jiangsu Hengrui, and Fresenius for $7.0 million. This settlement grants the defendants a volume-limited license to sell generic bupivacaine liposome injectable suspension starting in early 2030.
- Debt Refinancing: In July 2025, the Company entered into a new $300.0 million Revolving Credit Facility with Wells Fargo, refinancing its Term Loan A facility. The Company also repaid the remaining $202.5 million of its 2025 Convertible Senior Notes at maturity in August 2025.
- Share Repurchases: The Board authorized a new $300.0 million share repurchase program in April 2025. The Company repurchased approximately 1.96 million shares for $50.4 million during the first half of 2025.
Investor Verification Checklist
- Legal Settlement Impact: Verify the long-term revenue implications of the $7.0 million settlement with generic competitors, specifically the volume-limited entry dates (early 2030) and the maximum market share caps (high 30s%) for generic EXPAREL.
- Restructuring Costs: Monitor Q3 2025 results for the anticipated $2.4–$2.8 million restructuring charges and the timeline for realizing the projected $13.0 million in annual operating expense savings from the manufacturing consolidation.
- PCRX-201 Progress: Track enrollment and interim analysis results for the Phase 2 ASCEND trial for PCRX-201, with enrollment expected to complete before the end of 2025.
- Debt Obligations: Confirm the terms and interest rates of the new $300.0 million Revolving Credit Facility and the status of the $287.5 million 2029 Convertible Senior Notes, noting the conversion price of $39.56 per share.
- Tax Legislation: Assess the impact of the "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025 on the Company's deferred tax assets and liabilities, as the Company is currently evaluating the financial statement impact.